Valuation : Abion Inc.

Market Cap 60.91B 44.87M 38.6M 36.23M 33.14M 61.86M 4.24B 62.35M 429M 167M 2.17B 168M 165M 6.98B P/E 2024
-4.02x
P/E 2025 -7.21x
Enterprise Value 32.57B 23.99M 20.65M 19.37M 17.73M 33.08M 2.27B 33.35M 229M 89.25M 1.16B 90.11M 88.14M 3.73B EV / Sales 2024
282x
EV / Sales 2025 288x
Free-Float
73.67%
Yield 2024 *
-
Yield 2025 -
07/04 ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs CI
04/04/25 Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc RE
30/12/24 Nuon Co., Ltd. completed the acquisition of 4.06% stake in ABION Inc. from KPM TECH Co., Ltd.. CI
26/12/24 KPM TECH Co., Ltd. announced that it has received KRW 5.999999711 billion in funding from ABION Inc. CI
23/12/24 Nuon Co., Ltd. agreed to acquire 4.06% stake in ABION Inc. from KPM TECH Co., Ltd. for KRW 8 billion. CI
23/12/24 ABION Inc. announced that it has received KRW 8.0011152 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
18/12/24 KPM TECH Co., Ltd. announced that it expects to receive KRW 5.999999711 billion in funding from ABION Inc. CI
05/12/24 ABION Inc. completed the acquisition of 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc.. CI
05/12/24 ABION Inc. announced that it has received KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
11/11/24 ABION Inc. announced that it expects to receive KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
11/11/24 ABION Inc. agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. for KRW 20.1 billion. CI
28/10/24 ABION Inc. announced that it expects to receive KRW 9.999995616 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
28/12/23 Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc. CI
1 day-2.03%
1 month+1.96%
3 months-62.94%
6 months-78.57%
Current year-78.40%
1 month 587
Extreme 587
1,093
Current year 570
Extreme 570
4,335
1 year 570
Extreme 570
4,510
3 years 570
Extreme 570
7,277.78
5 years 570
Extreme 570
14,694.44
10 years 570
Extreme 570
14,694.44
Manager TitleAgeSince
Chief Executive Officer 55 01/08/2010
Director of Finance/CFO 45 28/03/2025
Chief Operating Officer 46 01/01/2026
Director TitleAgeSince
Director/Board Member 55 31/12/2014
Director/Board Member 56 25/03/2022
Director/Board Member 70 -
Date Insider Type Main position Quantity % Market Cap. Importance
8/12/25 Free 27 0.0001% -
8/12/25 Buy 115 0.0002%
8/12/25 Free 92 0.0002% -
Change 5-day change 1-year change 3-year change Capi.($)
-2.03%-.--%-77.88%-85.12% 44.85M
+0.41%-1.65%+39.85%+95.40% 68.87B
+1.31%+1.65%+50.56%+90.80% 65.29B
+0.04%+4.36%-11.72%+380.39% 27.65B
+2.97%-0.10%+41.86%+14.84% 25.77B
-0.90%-7.65%+2.45%-15.67% 26.08B
+1.01%+1.76%+32.99%-17.16% 20.14B
+3.45%-14.83%+225.22%+389.50% 17.03B
+0.77%-4.55%-0.36%+549.41% 15.03B
+1.03%+7.00%+59.98%+165.51% 14.5B
Average +0.81%-4.16%+36.29%+156.79% 28.04B
Weighted average by Cap. +0.98%-1.64%+43.59%+142.40%

Financials

2024 2025
Net sales 760M 560K 481K 452K 413K 772K 52.9M 778K 5.34M 2.08M 27.03M 2.1M 2.06M 87.06M 880M 648K 558K 523K 479K 894K 61.29M 901K 6.19M 2.41M 31.32M 2.43M 2.38M 101M
Net income -43.38B -31.96M -27.49M -25.8M -23.61M -44.06M -3.02B -44.41M -305M -119M -1.54B -120M -117M -4.97B -29.06B -21.41M -18.42M -17.29M -15.81M -29.52M -2.02B -29.75M -204M -79.63M -1.03B -80.39M -78.64M -3.33B
Net Debt 14.05B 10.35M 8.9M 8.35M 7.64M 14.27M 978M 14.38M 98.83M 38.49M 500M 38.85M 38.01M 1.61B -28.33B -20.87M -17.96M -16.85M -15.42M -28.78M -1.97B -29M -199M -77.63M -1.01B -78.37M -76.67M -3.25B
Logo Abion Inc.
ABION Inc. is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics.
Employees
-
  1. Stock Market
  2. Stocks
  3. A203400 Stock